Compare ARES & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARES | GEHC |
|---|---|---|
| Founded | 1997 | 1892 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Computer Software: Prepackaged Software |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.4B | 38.9B |
| IPO Year | 2014 | N/A |
| Metric | ARES | GEHC |
|---|---|---|
| Price | $131.85 | $84.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $190.67 | $88.75 |
| AVG Volume (30 Days) | 2.6M | ★ 3.5M |
| Earning Date | 02-05-2026 | 02-04-2026 |
| Dividend Yield | ★ 3.40% | 0.18% |
| EPS Growth | 9.11 | ★ 32.35 |
| EPS | 2.38 | ★ 4.83 |
| Revenue | $5,355,558,000.00 | ★ $20,246,000,000.00 |
| Revenue This Year | $20.08 | $6.42 |
| Revenue Next Year | $21.33 | $4.34 |
| P/E Ratio | $55.20 | ★ $16.31 |
| Revenue Growth | ★ 45.54 | 3.51 |
| 52 Week Low | $110.63 | $57.65 |
| 52 Week High | $200.49 | $94.80 |
| Indicator | ARES | GEHC |
|---|---|---|
| Relative Strength Index (RSI) | 21.62 | 56.76 |
| Support Level | $145.46 | $78.23 |
| Resistance Level | $152.56 | $83.21 |
| Average True Range (ATR) | 5.59 | 2.10 |
| MACD | -3.25 | -0.05 |
| Stochastic Oscillator | 13.34 | 81.83 |
Ares Management is one of the world's largest alternative-asset managers, with $595.7 billion in total assets under management, or AUM, including $367.6 billion in fee-earning AUM, at the end of September 2025. The company has four main business segments: private credit ($391.5 billion in total AUM and $240.2 billion in fee-earning AUM), private equity, ($25.1 billion/$11.8 billion), real estate/real assets ($132.4 billion/$80.5 billion), and other alternatives ($46.7 billion/$35.1 billion). The firm primarily serves institutional investors (80% of AUM) and high-net-worth individuals (20%). Ares operates through more than 35 offices in over 15 countries around the globe.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).